Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Kumar SK, et al. Among authors: badros az. Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12. Leukemia. 2017. PMID: 28620163
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Shaughnessy J, et al. Blood. 2003 May 15;101(10):3849-56. doi: 10.1182/blood-2002-09-2873. Epub 2003 Jan 16. Blood. 2003. PMID: 12531801 Free article.
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Badros AZ, et al. J Clin Oncol. 2005 Jun 20;23(18):4089-99. doi: 10.1200/JCO.2005.14.381. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867202 Clinical Trial.
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. Stadtmauer EA, et al. Clin Adv Hematol Oncol. 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2. Clin Adv Hematol Oncol. 2007. PMID: 18000495 No abstract available.
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group. Hussein MA, et al. Leukemia. 2008 Aug;22(8):1479-84. doi: 10.1038/leu.2008.127. Epub 2008 May 29. Leukemia. 2008. PMID: 18509352 No abstract available.
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. Dispenzieri A, et al. Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20. Leukemia. 2009. PMID: 19020545 Review.
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. Dimopoulos M, et al. Leukemia. 2009 Sep;23(9):1545-56. doi: 10.1038/leu.2009.89. Epub 2009 May 7. Leukemia. 2009. PMID: 19421229 Review.
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Richardson P, et al. Among authors: badros az. Blood. 2009 Jul 23;114(4):772-8. doi: 10.1182/blood-2008-12-196238. Epub 2009 May 26. Blood. 2009. PMID: 19471019 Free article. Clinical Trial.
131 results